Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Non-Current Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $183.6 million as the latest value for Q3 2025.

  • Quarterly Total Non-Current Liabilities rose 23.52% to $183.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $183.6 million through Sep 2025, up 23.52% year-over-year, with the annual reading at $204.2 million for FY2024, 37.76% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $183.6 million at Editas Medicine, down from $186.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $204.2 million in Q4 2024, with the low at $142.5 million in Q1 2024.
  • Average Total Non-Current Liabilities over 4 years is $168.0 million, with a median of $153.6 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities dropped 3.5% in 2023, then skyrocketed 37.76% in 2024.
  • Over 4 years, Total Non-Current Liabilities stood at $153.6 million in 2022, then decreased by 3.5% to $148.3 million in 2023, then skyrocketed by 37.76% to $204.2 million in 2024, then dropped by 10.1% to $183.6 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $183.6 million, $186.8 million, and $194.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.